Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).

Autor: Rinnerthaler, Gabriel1,2,3 g.rinnerthaler@salk.at, Gampenrieder, Simon Peter1,2,3 s.gampenrieder@salk.at, Petzer, Andreas4 andreas.petzer@ordensklinikum.at, Burgstaller, Sonja5 sonja.burgstaller@klinikum-wegr.at, Fuchs, David6 david.fuchs@kepleruniklinikum.at, Rossmann, Dieter7 dieter.rossmann@gespag.at, Balic, Marija8 marija.balic@medunigraz.at, Egle, Daniel9 daniel.egle@i-med.ac.at, Rumpold, Holger10 holger.rumpold@lkhf.at, Singer, Christian F.11 christian.singer@meduniwien.ac.at, Bartsch, Rupert12 rupert.bartsch@meduniwien.ac.at, Petru, Edgar13 edgar.petru@medunigraz.at, Melchardt, Thomas1,2,3 t.melchardt@salk.at, Ulmer, Hanno14 hanno.ulmer@i-med.ac.at, Mlineritsch, Brigitte1,2,3 b.mlineritsch@salk.at, Greil, Richard1,2,3 ag.rinnerthaler@salk.at
Zdroj: BMC Cancer. 11/6/2018, Vol. 18 Issue 1, p1-9. 9p. 1 Diagram, 2 Charts.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje